A detailed history of Gts Securities LLC transactions in Kinnate Biopharma Inc. stock. As of the latest transaction made, Gts Securities LLC holds 60,038 shares of KNTE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,038
Holding current value
$0
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.24 - $2.66 $134,485 - $159,701
60,038 New
60,038 $159,000

Others Institutions Holding KNTE

About Kinnate Biopharma Inc.


  • Ticker KNTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,145,600
  • Description
  • Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...
More about KNTE
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.